Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.

Literature DB >> 16208029

Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation.

Corrado Girmenia¹, Maria Luisa Moleti, Alessandra Micozzi, Anna Paola Iori, Walter Barberi, Robin Foà, Pietro Martino.

Abstract

We report a case of breakthrough invasive zygomycosis in a stem cell transplant recipient who was receiving caspofungin for treatment of a breakthrough Candida krusei fungemia that occurred during fluconazole prophylaxis. Also, patients receiving the echinocandin caspofungin remain at risk for pathogens, such as zygomycetes, that are intrinsically resistant to this agent.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2005 PMID： 16208029 PMCID： PMC1248476 DOI： 10.1128/JCM.43.10.5395-5396.2005

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

15 in total

1. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate.

Authors: Daniel Goodman; Eric Pamer; Ann Jakubowski; Carol Morris; Kent Sepkowitz
Journal: Clin Infect Dis Date: 2002-06-27 Impact factor: 9.079

2. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

Authors: Alexander Imhof; S Arunmozhi Balajee; David N Fredricks; Janet A Englund; Kieren A Marr
Journal: Clin Infect Dis Date: 2004-08-13 Impact factor: 9.079

3. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis.

Authors: A Safdar; S O'Brien; I F Kouri
Journal: Bone Marrow Transplant Date: 2004-09 Impact factor: 5.483

4. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors: Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal: N Engl J Med Date: 2004-02-26 Impact factor: 91.245

5. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis.

Authors: Laura Cudillo; Corrado Girmenia; Stefania Santilli; Alessandra Picardi; Teresa Dentamaro; Andrea Tendas; Paolo de Fabritiis
Journal: Clin Infect Dis Date: 2005-04-15 Impact factor: 9.079

6. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors: Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245

7. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.

Authors: J R Wingard; M H White; E Anaissie; J Raffalli; J Goodman; A Arrieta
Journal: Clin Infect Dis Date: 2000-11-07 Impact factor: 9.079

8. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.

Authors: M H White; R A Bowden; E S Sandler; M L Graham; G A Noskin; J R Wingard; M Goldman; J A van Burik; A McCabe; J S Lin; M Gurwith; C B Miller
Journal: Clin Infect Dis Date: 1998-08 Impact factor: 9.079

9. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis.

Authors: Greg T Siwek; Kirsty J Dodgson; Margarida de Magalhaes-Silverman; Luther A Bartelt; Sara B Kilborn; Peter L Hoth; Daniel J Diekema; Michael A Pfaller
Journal: Clin Infect Dis Date: 2004-07-30 Impact factor: 9.079

10. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.

Authors: Thomas J Walsh; Hedy Teppler; Gerald R Donowitz; Johan A Maertens; Lindsey R Baden; Anna Dmoszynska; Oliver A Cornely; Michael R Bourque; Robert J Lupinacci; Carole A Sable; Ben E dePauw
Journal: N Engl J Med Date: 2004-09-30 Impact factor: 91.245

4 in total

1. Mucormycosis in Mato Grosso, Brazil: a case reports, caused by Rhizopus microsporus var. oligosporus and Rhizopus microsporus var. rhizopodiformis.

Authors: Luciano Corrêa Ribeiro; Bodo Wanke; Manuela da Silva; Luciana Basili Dias; Renato Mello; Fernando Artur Pena Borges Canavarros; Diniz Pereira Leite; Rosane Christine Hahn
Journal: Mycopathologia Date: 2011-09-28 Impact factor: 2.574